|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69.95 USD | -1.14% |
|
-6.01% | +6.76% |
| 06-02 | ASTRAZENECA : Buy rating from JP Morgan | ZD |
| 06-02 | UK's FTSE 100 closes around flat as staples, healthcare losses eclipse energy gains | RE |
| Capitalization | 217B 188B 177B 161B 298B 18,800B 336B 2,100B 804B 8,612B 814B 797B 31,659B | P/E ratio 2025 * |
21.9x | P/E ratio 2026 * | 18.2x |
|---|---|---|---|---|---|
| Enterprise value | 237B 206B 194B 176B 326B 20,555B 367B 2,296B 879B 9,416B 891B 872B 34,614B | EV / Sales 2025 * |
4.1x | EV / Sales 2026 * | 3.76x |
| Free-Float |
96.62% | Yield 2025 * |
2.3% | Yield 2026 * | 2.41% |
More valuation ratios
* Estimated data
More news
Last Transcript: AstraZeneca PLC
More press releases
| 1 day | -1.14% | ||
| 1 week | -6.01% | ||
| Current month | -3.95% | ||
| 1 month | +0.04% | ||
| 3 months | -8.59% | ||
| 6 months | +7.04% | ||
| Current year | +6.76% |
| 1 week | 69.66 |  | 74.76 |
| 1 month | 69.47 | | 75.38 |
| Current year | 61.24 | | 78.36 |
| 1 year | 61.24 | | 87.68 |
| 3 years | 52.65 | | 87.68 |
| 5 years | 46.48 | | 87.68 |
| 10 years | 25.55 | | 87.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 65 | 30/09/2012 |
Aradhana Sarin
DFI | Director of Finance/CFO | 51 | 31/07/2021 |
Sharon Barr
CTO | Chief Tech/Sci/R&D Officer | - | 31/07/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 69 | 05/04/1999 | |
Pascal Soriot
BRD | Director/Board Member | 65 | 30/09/2012 |
Philip Broadley
BRD | Director/Board Member | 64 | 26/04/2017 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 0.99% | 1,152 M€ | +5.69% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.14% | -6.01% | - | - | 220B | ||
| -2.84% | -6.91% | -13.91% | +162.20% | 705B | ||
| -0.62% | -4.65% | +1.36% | -11.61% | 363B | ||
| -2.58% | -7.83% | -52.12% | +25.00% | 333B | ||
| -0.10% | -3.02% | +7.65% | +34.00% | 328B | ||
| -0.27% | -3.86% | +3.72% | -14.84% | 255B | ||
| -0.34% | -2.34% | +0.59% | +19.15% | 228B | ||
| -0.29% | -3.24% | -39.03% | -6.57% | 199B | ||
| -0.10% | -2.00% | -6.63% | +23.27% | 156B | ||
| +0.38% | -2.32% | -13.59% | -48.48% | 136B | ||
| Average | -0.13% | -3.76% | -12.44% | +20.23% | 300.13B | |
| Weighted average by Cap. | -0.10% | -4.45% | -12.49% | +46.60% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 57.83B 50.16B 47.25B 42.93B 79.43B 5,009B 89.49B 560B 214B 2,295B 217B 212B 8,435B | 61.18B 53.07B 49.99B 45.42B 84.03B 5,299B 94.68B 592B 227B 2,428B 230B 225B 8,923B |
| Net income | 9.92B 8.6B 8.1B 7.36B 13.62B 859B 15.35B 95.97B 36.73B 394B 37.22B 36.43B 1,447B | 11.95B 10.36B 9.76B 8.87B 16.41B 1,035B 18.49B 116B 44.24B 474B 44.83B 43.87B 1,742B |
| Net Debt | 20.26B 17.58B 16.56B 15.04B 27.83B 1,755B 31.36B 196B 75.03B 804B 76.03B 74.42B 2,955B | 12.88B 11.17B 10.52B 9.56B 17.69B 1,115B 19.93B 125B 47.68B 511B 48.32B 47.29B 1,878B |
More financial data
* Estimated data
Employees
94,300
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/06/25 | 69.95 $ | -1.14% | 6,295,981 |
| 18/06/25 | 70.76 $ | -0.30% | 3,371,567 |
| 17/06/25 | 70.97 $ | -3.51% | 4,263,587 |
| 16/06/25 | 73.55 $ | -1.17% | 3,419,053 |
| 13/06/25 | 74.42 $ | -0.77% | 3,131,593 |
Delayed Quote Nasdaq, June 20, 2025 at 09:00 pm
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
139.98USD
Average target price
179.12USD
Spread / Average Target
+27.96%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AZN Stock
- AZN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition